Analysis and Investigation of the Effectiveness of Irbesartan Hydrochloro-thiazide Combined with Metoprolol in the Treatment of Chronic Conges-tive Heart Failure
Objective To analyze the effect of implementing irbesartan hydrochlorothiazide + metoprolol treatment for chronic congestive heart failure.Methods 200 cases of chronic congestive heart failure patients in the comprehensive internal medicine department of Zhengding 256 Hospital from November 2020 to November 2023 were taken as re-search subjects,and rolled the dice to group them into reference group and practice group,each with 100 cases.The reference group carried out the treatment of irbesartan hydrochlorothiazide,and the practice group increased the treat-ment of metoprolol.The efficacy,left ventricular function,regression and count adverse reactions were compared of the two groups.Results The total effective rate of 98.00%in the practice group was higher than 91.00%in the refer-ence group,and the difference was statistically significant(x2=4.714,P＜0.05).After treatment,the left ventricular ejection fraction of the practice group was higher than that of the reference group,and the left ventricular end-diastolic internal diameter was lower than that of the reference group,and the differences were statistically significant(both P＜0.05).After treatment,the 6 min walking test of the practice group was higher than that of the reference group,and the B-type natriuretic peptideogen was lower than that of the reference group,and the differences were sta-tistically significant(both P＜0.05).Comparison of adverse reactions between the two groups,the difference was not sta-tistically significant(P＞0.05).Conclusion Irbesartan hydrochlorothiazide + metoprolol after co-administration of fewer adverse reactions,can effectively improve the left ventricular function,reduce myocardial injury,and improve the efficiency,and this treatment method is more applicable to chronic congestive heart failure.
万方数据
维普
